• 重慶醫(yī)科大學(xué)附屬第一醫(yī)院普外科（重慶400016）;

目的評(píng)價(jià)整合素在腫瘤血管生成中的作用。方法復(fù)習(xí)國(guó)內(nèi)、外文獻(xiàn)，并作綜述報(bào)道。結(jié)果整合素在腫瘤血管生成中起重要作用，且與血管生長(zhǎng)因子VEGF、bFGF、TGFβ等有密切關(guān)系。結(jié)論整合素抑制劑將是一個(gè)有效的抗腫瘤方法。

引用本文： 高銳,綜述,姚榛祥,審校. 整合素與腫瘤血管生成. 中國(guó)普外基礎(chǔ)與臨床雜志, 2002, 9(3): 213-214. doi: 復(fù)制

1. Springer TA. Folding of the Nterminal, ligandbinding region of integrin αsubunit into a bpropeller domain [J]. Proc Natl Acad Sci USA, 1997; 94(1)∶65.
2. Mizejewski GJ. Role of integrin in cancer: survey of expression patterns [J]. Proc Soc Exp Bio Med, 1999; 222(2)∶124.
3. Mizejewske GJ. Afeteprotein as a biologic response modifier: relevance to domain and subdomain structure [J]. Proc Soc Exp Bio Med, 1997; 215(4)∶333.
4. Gui GP, Puddlegoot JR, Vinson GP, et al. In vitro regulation of human breast cancer cell adhesion and invasion via integrin receptors to the extracellular matrix [J]. Br J Surg, 1995; 82(9)∶1192.
5. Drake CJ, Cheresh DA, Little CD. A antagonist of integrin αⅤβ3 prevent maturations of blood vessels during embryonic neovascularization [J]. J Cell Science, 1995; 108(pt 7)∶2655.
6. Carron CP, Meyer DM, Pegg JA, et al. A peptidomimetic antagonist of the integrin αⅤβ3 inhibits leydig cell tumor growth and the development of hypercalcemia of malignanoy [J]. Cancer Res, 1998; 58(9)∶1930.
7. Kerr JS, Wexler RS, Mousa SA, et al. Novel small molecue αⅤ integrin antagonists comparative anticancer efficacy with known angiogenesis inhibitors [J]. Anticancer Res, 1999; 19(2a)∶959.
8. Stromblad S, Becker JC, Yebra M. Suppresion of p53 activity and p21WAF/CIP1 expression by vascular cell integrin αⅤβ3 during angiogenesis [J].J Clin Investig, 1996; 7(2)∶426.
9. Petitclerc E, Stromblad S, Von Schalscha TL, et al. Integrin αⅤβ3 promotes M21 melanoma growth in human skin by regulating tumor cell survival [J]. Cancer Res, 1999; 59(11)∶2724.
10. Lew JM, Cheresh DA, Schwartz MA. Protein kinase C regulates αⅤβ5 dependent cytokeletal association and focal adhesion kinase phosphorylation [J]. J Cell Biol, 1999; 134(5)∶1323.
11. Yebra M, Parrg GCN, Stromblad S, et al. Requirement of receptor bound urokinase type plasminogen activator for integrin αⅤβ5 directed cell migration [J]. J Biol Chem, 1996; 271(46)∶29393.
12. Kim S, Bell K, Mousa SA, et al. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell binding domain of fibronectin [J]. Am J Patho, 2000; 156(4)∶1345.
13. Scheller M, Vuoric K, Ruoslahti E. α5β3 integrin associates with activated insulin and PDGF beta receptors and potentiates the biological activity of PDGF [J]. EMBO J, 1997; 16(18)∶5600.
14. Donald R, Kevin P, Julie E, et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins [J]. Proc Natl Acad Sci USA, 1997; 94(pp)∶13612.
15. Senger DR, Ledbetter SR, Claffey KP, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanism involving the αⅤβ3 integrin, osteoponin and thrombin [J]. Am J Pathol, 1996; 149(1)∶293.
16. Sato Y. Transciption factor ETS1 as a molecular target for angiogenesis inhibition [J]. Hum Cell, 1998; 11(4)∶207.
17. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha Ⅴ beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels [J]. Cell, 1994; 79(7)∶1157.
18. Chiang HS, Swaim MW, Huang TF. Characterization of platelet aggregation induced by human colon adenocarcinoma cell and its inhibition by snake venom peptides trigramin and rhdostomin [J]. Breast Cancer Res Treat, 1995; 33(3)∶225.
19. Dechantsreiter MA, Planker E, Matha B, et al. Nmethylated cyclic RGD reptides as highly active and selective αⅤβ3 integrin antagonists [J]. J Med Chem, 1999; 42(16)∶3033.
  1. 1. Springer TA. Folding of the Nterminal, ligandbinding region of integrin αsubunit into a bpropeller domain [J]. Proc Natl Acad Sci USA, 1997; 94(1)∶65.
  2. 2. Mizejewski GJ. Role of integrin in cancer: survey of expression patterns [J]. Proc Soc Exp Bio Med, 1999; 222(2)∶124.
  3. 3. Mizejewske GJ. Afeteprotein as a biologic response modifier: relevance to domain and subdomain structure [J]. Proc Soc Exp Bio Med, 1997; 215(4)∶333.
  4. 4. Gui GP, Puddlegoot JR, Vinson GP, et al. In vitro regulation of human breast cancer cell adhesion and invasion via integrin receptors to the extracellular matrix [J]. Br J Surg, 1995; 82(9)∶1192.
  5. 5. Drake CJ, Cheresh DA, Little CD. A antagonist of integrin αⅤβ3 prevent maturations of blood vessels during embryonic neovascularization [J]. J Cell Science, 1995; 108(pt 7)∶2655.
  6. 6. Carron CP, Meyer DM, Pegg JA, et al. A peptidomimetic antagonist of the integrin αⅤβ3 inhibits leydig cell tumor growth and the development of hypercalcemia of malignanoy [J]. Cancer Res, 1998; 58(9)∶1930.
  7. 7. Kerr JS, Wexler RS, Mousa SA, et al. Novel small molecue αⅤ integrin antagonists comparative anticancer efficacy with known angiogenesis inhibitors [J]. Anticancer Res, 1999; 19(2a)∶959.
  8. 8. Stromblad S, Becker JC, Yebra M. Suppresion of p53 activity and p21WAF/CIP1 expression by vascular cell integrin αⅤβ3 during angiogenesis [J].J Clin Investig, 1996; 7(2)∶426.
  9. 9. Petitclerc E, Stromblad S, Von Schalscha TL, et al. Integrin αⅤβ3 promotes M21 melanoma growth in human skin by regulating tumor cell survival [J]. Cancer Res, 1999; 59(11)∶2724.
  10. 10. Lew JM, Cheresh DA, Schwartz MA. Protein kinase C regulates αⅤβ5 dependent cytokeletal association and focal adhesion kinase phosphorylation [J]. J Cell Biol, 1999; 134(5)∶1323.
  11. 11. Yebra M, Parrg GCN, Stromblad S, et al. Requirement of receptor bound urokinase type plasminogen activator for integrin αⅤβ5 directed cell migration [J]. J Biol Chem, 1996; 271(46)∶29393.
  12. 12. Kim S, Bell K, Mousa SA, et al. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell binding domain of fibronectin [J]. Am J Patho, 2000; 156(4)∶1345.
  13. 13. Scheller M, Vuoric K, Ruoslahti E. α5β3 integrin associates with activated insulin and PDGF beta receptors and potentiates the biological activity of PDGF [J]. EMBO J, 1997; 16(18)∶5600.
  14. 14. Donald R, Kevin P, Julie E, et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins [J]. Proc Natl Acad Sci USA, 1997; 94(pp)∶13612.
  15. 15. Senger DR, Ledbetter SR, Claffey KP, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanism involving the αⅤβ3 integrin, osteoponin and thrombin [J]. Am J Pathol, 1996; 149(1)∶293.
  16. 16. Sato Y. Transciption factor ETS1 as a molecular target for angiogenesis inhibition [J]. Hum Cell, 1998; 11(4)∶207.
  17. 17. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha Ⅴ beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels [J]. Cell, 1994; 79(7)∶1157.
  18. 18. Chiang HS, Swaim MW, Huang TF. Characterization of platelet aggregation induced by human colon adenocarcinoma cell and its inhibition by snake venom peptides trigramin and rhdostomin [J]. Breast Cancer Res Treat, 1995; 33(3)∶225.
  19. 19. Dechantsreiter MA, Planker E, Matha B, et al. Nmethylated cyclic RGD reptides as highly active and selective αⅤβ3 integrin antagonists [J]. J Med Chem, 1999; 42(16)∶3033.